Predictors of graft patency 3 years after coronary artery bypass graft surgery. Department of Veterans Affairs Cooperative Study Group No. 297.

OBJECTIVES The purpose of this analysis was to define the factors that predict 3-year graft patency. BACKGROUND The success of coronary artery bypass graft surgery (CABG) is dependent on vein graft patency after the operation. It has been well established by a series of Department of Veterans Affairs Cooperative Trials that aspirin (325 mg daily) improves saphenous vein graft patency early (7 to 10 days) and at 1 year, but not at 3 years after CABG. This analysis, based on one of these trials, defined factors that predict 3-year graft patency. METHODS This analysis consisted of 266 patients, with 656 grafts that were patent 7 to 10 days after the operation, who underwent 3-year catheterization. To determine which patient-specific and/or graft-specific factors, or both, predict graft occlusion, a multivariate logistic regression analysis in terms of latent variables was used. It yielded a model that also took into account possible intraclass correlations. RESULTS For a vein graft that was patent at 7 to 10 days after the operation, the positive predictors, according to univariate analysis, for that graft being patent at 3 years were cross-clamp time < or = 80 min (p < 0.001), vein preservation solution temperature < or = 5 degrees C (p = 0.009), bypass time < or = 2 h (p = 0.042), number of proximal anastomoses < or = 2 (p = 0.018), operation time < or = 5 h (p = 0.044) and continuous versus intermittent cross-clamp technique (p = 0.024). There was also a trend with regard to recipient artery diameter > 1.5 mm (p = 0.063), serum cholesterol < or = 225 mg/dl (p = 0.084) and single versus sequential or Y vein graft (p = 0.060). Factors not predictive of 3-year patency were age, race, smoking history, high density lipoprotein cholesterol, vein source (thigh vs. calf), coronary artery grafted and aspirin treatment. Of all the predictors obtained in the univariate analysis, the only variables that were sufficient to yield a good model within the multivariate analysis were solution temperature (p = 0.004), serum cholesterol (p = 0.024), number of proximal anastomoses (p = 0.032) and recipient artery diameter (p = 0.034). CONCLUSIONS For a patient with patent vein grafts 7 to 10 days after the operation, predictors of 3-year graft patency are more closely related to operative techniques and underlying disease and not to aspirin treatment.

[1]  M. Bourassa,et al.  Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. , 1984, Circulation.

[2]  F. Loop,et al.  Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. , 1985, The Journal of thoracic and cardiovascular surgery.

[3]  Thomas E. Moritz,et al.  Internal mammary artery and saphenous vein graft patency. Effects of aspirin. , 1990, Circulation.

[4]  M. Bourassa,et al.  Changes in Grafts and Coronary Arteries After Saphenous Vein Aortocoronary Bypass Surgery: Results at Repeat Angiography , 1982, Circulation.

[5]  G. Sanz,et al.  Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC) , 1990, Circulation.

[6]  V. Gebski,et al.  Immediate Postoperative Aspirin Improves Vein Graft Patency Early and Late After Coronary Artery Bypass Graft Surgery: A Placebo‐Controlled, Randomized Study , 1991, Circulation.

[7]  J. Copeland,et al.  Starting Aspirin Therapy After Operation: Effects on Early Graft Patency , 1991, Circulation.

[8]  M. Pfisterer,et al.  Prevention of one-year vein-graft occlusion after aortocoronary- bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants , 1993, The Lancet.

[9]  Thomas E. Moritz,et al.  Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. , 1988, Circulation.

[10]  J. Copeland,et al.  Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. , 1989, Circulation.

[11]  L. Campeau,et al.  Coronary artery bypass grafting with saphenous vein. , 1989, Circulation.

[12]  Thomas E. Moritz,et al.  Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study. , 1994, Circulation.

[13]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[14]  R. Boldorini,et al.  University of Wisconsin solution and human saphenous vein graft preservation: preliminary anatomic report. , 1993, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  Y. Qu,et al.  Latent Variable Models for Clustered Dichotomous Data with Multiple Subclusters , 1992 .

[16]  W G Henderson,et al.  The statistical analysis of graft patency data in a clinical trial of antiplatelet agents following coronary artery bypass grafting. , 1988, Controlled clinical trials.

[17]  A. Whittemore Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study: Steven Goldman MD, Jack Copeland, MD, Thomas Moritz, MS, et al. Circulation 1988;77:1324-32 , 1989 .

[18]  J. Copeland,et al.  Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. , 1994, The American journal of physiology.

[19]  V. Fuster,et al.  Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. , 1984, The New England journal of medicine.

[20]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[21]  F. Spencer,et al.  The factors influencing early patency of coronary artery bypass vein grafts: correlation of angiographic and ultrastructural findings. , 1982, The Journal of thoracic and cardiovascular surgery.

[22]  W. Quist,et al.  An improved technique for preservation of endothelial morphology in vein grafts. , 1981, Surgery.

[23]  S. Wacholder,et al.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. , 1984, The New England journal of medicine.